At Gene Therapy for Neurological Disorders (GTxN), we work selectively with service providers to help our specialized group of drug developers to progress their CNS therapeutic
GTxN is the only industry-focused meeting dedicated to helping drug developers successfully develop gene therapies for CNS indications.
Network with leading minds from the likes of Takeda, Servier, Axovant, UCB and Sanofi to demonstrate how your products and services can help them to overcome their translational challenges and accelerate their gene therapy candidate to market.
|Demonstrate your experience in vector engineering and gene therapy development|
|Showcase your high quality preclinical models and novel model innovations to improve the translatability of preclinical research|
|Present your large mammal expertise to CNS decision makers actively seeking more advanced non-rodent models|
|Introduce the latest drug delivery devices to show the potential for successful administration|
|Establish your preclinical experience to improve the predictability of preclinical gene therapy research|
|Reveal how your technology platform may improve the efficiency and accuracy of drug developers research|
As one of the few selected service providers at GTxN, we will work with you to build a bespoke partnership package to ensure you meet your 2020 business needs.